Sabirin Faezah, Lim Siong Meng, Neoh Chin Fen, Ramasamy Kalavathy
Collaborative Drug Discovery Research (CDDR) Group, Faculty of Pharmacy, Universiti Teknologi MARA (UiTM), Cawangan Selangor, Kampus Puncak Alam, Bandar Puncak Alam, Malaysia.
Centre of Preclinical Science Studies, Faculty of Dentistry, Universiti Teknologi MARA (UiTM), Cawangan Selangor, Kampus Sungai Buloh, Sungai Buloh, Malaysia.
Front Nutr. 2022 Apr 11;9:844374. doi: 10.3389/fnut.2022.844374. eCollection 2022.
Probiotic supplements have been increasingly reported for their usefulness in delaying the development and progression of non-alcoholic fatty liver disease (NAFLD). Literature on the impact of probiotics on NAFLD covered various aspects of the disease. This study was undertaken to systematically review findings on hepatoprotection of probiotics against NAFLD. The literature search was performed through Cochrane, PubMed/MEDLINE, Embase, and Web of Science databases. Interventions of known probiotics in NAFLD-induced animal model with at least one measurable NAFLD-related parameter were included. The data were extracted by all authors independently. Quality assessment was conducted using the Systematic Review Center for Laboratory animal Experimentation (SYRCLE's) Risk of Bias (RoB) tool. -values of measures were compared inter- and intra-study for each parameter. Forty-four probiotic-based studies of NAFLD-induced rodents were shortlisted. The majority of the studies were presented with low/unclear risk of bias. Probiotics improved the histopathology of NAFLD rodents (primary outcome). Most of the probiotic-supplemented NAFLD rodents were presented with mixed effects on serum liver enzymes but with improved hepatic and serum lipid profiles (including increased serum high-density lipoprotein cholesterol). The findings were generally accompanied by downregulation of hepatic lipogenic, oxidative, and inflammatory signallings. Probiotics were found to modulate gut microbiota composition and its products, and intestinal permeability. Probiotics also resulted in better glycaemic control and reduced liver weight. Altogether, the present qualitative appraisals strongly implied the hepatoprotective potential of probiotics against NAFLD .
越来越多的报道称益生菌补充剂在延缓非酒精性脂肪性肝病（NAFLD）的发生和发展方面具有作用。关于益生菌对NAFLD影响的文献涵盖了该疾病的各个方面。本研究旨在系统综述益生菌对NAFLD肝保护作用的研究结果。通过Cochrane、PubMed/MEDLINE、Embase和Web of Science数据库进行文献检索。纳入已知益生菌在至少有一个可测量的NAFLD相关参数的NAFLD诱导动物模型中的干预措施。数据由所有作者独立提取。使用实验动物系统评价中心（SYRCLE）的偏倚风险（RoB）工具进行质量评估。对每个参数在研究间和研究内比较测量值的P值。筛选出44项基于益生菌的NAFLD诱导啮齿动物研究。大多数研究显示偏倚风险低/不明确。益生菌改善了NAFLD啮齿动物的组织病理学（主要结果）。大多数补充益生菌的NAFLD啮齿动物血清肝酶呈现混合效应，但肝和血脂谱得到改善（包括血清高密度脂蛋白胆固醇升高）。这些发现通常伴随着肝脏脂肪生成、氧化和炎症信号的下调。发现益生菌可调节肠道微生物群组成及其产物以及肠道通透性。益生菌还能更好地控制血糖并减轻肝脏重量。总之，目前的定性评估强烈暗示了益生菌对NAFLD的肝保护潜力。
